Oramed Pharmaceuticals Inc.

ORMP

US68403P2039

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.46 ^USD	+6.96%		+8.37%	+6.49%

Mar. 19	Oramed Pharmaceuticals Inc. Appoints Yehuda Reznick as Director, Effective as of April 1, 2024	CI
Mar. 06	Oramed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Oramed Pharmaceuticals Inc.(TASE:ORMP) dropped from TA-125 Index

November 03, 2023 at 12:00 am EDT

Oramed Pharmaceuticals Inc. has been drooped from TA-125 Index.

Latest news about Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc. Appoints Yehuda Reznick as Director, Effective as of April 1, 2024	Mar. 19	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Oramed Pharmaceuticals Inc. Announces Resignation of Yadin Rozov from the Board of Directors	Jan. 19	CI
Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024	Dec. 19	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Oramed Pharmaceuticals Inc.(TASE:ORMP) dropped from TA-125 Index	Nov. 03	CI
Scilex Consummates Purchase of Securities Owned by Sorrento Therapeutics	23-09-21	MT
Scilex Holding Company announced that it has received $101.875 million in funding from Oramed Pharmaceuticals Inc.	23-09-20	CI
Oramed Pharmaceuticals Inc. cancelled the acquisition of 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q).	23-09-20	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Oramed Pharmaceuticals Inc. entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.	23-08-06	CI
Oramed Pharmaceuticals, Hefei Tianhui Biotech Sign Non-Binding Agreement to Form Joint Venture	23-08-02	MT
Oramed Pharmaceuticals Inc. Signs Term Sheet with Hefei Tianhui Biotech Co., Ltd. to Create Joint Venture to Advance Oral Drug Delivery Technology Globally	23-08-02	CI
Canaccord Genuity Adjusts Price Target on Oramed Pharmaceuticals to $2 From $3, Maintains Hold Rating	23-05-17	MT
Oramed Pharmaceuticals Says Hefei Tianhui Biotechnology Completes Phase 3 Trial of Oral Insulin; Shares Rise	23-05-15	MT
Oramed Pharmaceuticals Inc. Announces its Chinese Partner, Hefei Tianhui Biotechnology Co. Ltd. Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China	23-05-15	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Oramed Pharmaceuticals Inc. Appoints Ben Shapiro to Its Board of Directors	23-05-01	CI
Insider Buy: Oramed Pharmaceuticals	23-03-15	MT
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-06	CI
Oramed Pharmaceuticals Inc.(TASE:ORMP) added to TA-125 Index	23-02-06	CI
HC Wainwright Downgrades Oramed Pharmaceuticals to Neutral From Buy	23-01-17	MT
Health Care Down on Inflation Bets -- Health Care Roundup	23-01-12	DJ
Sector Update: Health Care Stocks Trim Early Declines	23-01-12	MT
Sector Update: Health Care Stocks Slipping in Recent Trading	23-01-12	MT

Chart Oramed Pharmaceuticals Inc.

Duration

Period

More charts

Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.

Sector

Biotechnology & Medical Research

Calendar

2024-07-09 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.46 USD

Average target price

4.25 USD

Spread / Average Target

+72.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ORAMED PHARMACEUTICALS INC.	+6.49%	99.68M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research